Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

Fig. 2

Proportion of subjects achieving no vomiting for the fosaprepitant regimen versus the control regimen: acute (0–24 h), delayed (25–120 h), and overall (0–120 h) no vomiting rates based on the Cochran-Mantel-Haenszel method, with stratification by sex (ITT population). a Subjects with GI or colorectal cancer. b Subjects with lung cancer. c Subjects with breast cancer. d Subjects with gynecologic cancer. CI confidence interval, GI gastrointestinal, ITT intention-to-treat, NV no vomiting

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us